Dotmatics releases Platform 22.1 - delivering new capabilities to streamline lab workflows
Latest Platform delivers new capabilities to streamline lab workflows and support customers’ data-informed decision making.
Centauri Therapeutics closes £24 million GBP Series A investment round
Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announces the close of its £24 million GBP (c. 32 million USD) Series A investment round.
OxDX raises £2.6M pre-seed funding to develop AI powered rapid diagnostic technology
Technology aims to improve speed, cost and accuracy of infectious disease diagnostics. The funding will be used to expand team and further validate technology.
Bio-Rad introduces anti-daratumumab antibodies
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38.
Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer
Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic.
Phico Therapeutics establishes Scientific Advisory Board
SAB will provide scientific oversight and strategic advice to support the progression Phico’s engineered phage antibacterial therapy, SASPject, through clinical trials.
Bio-Rad launches Anti-Pertuzumab Antibodies
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, introduces four inhibitory antibodies that are highly specific to pertuzumab (Perjeta).
Antiverse collaborates with top 20 pharma company to identify antibody drug candidates using AI Augmented Drug Discovery platform
Antiverse’s platform accurately identified diverse and rare antibodies. The project demonstrates potential of Antiverse’s platform to reduce time and costs associated with antibody drug discovery.
H.E.L Group appoints Rajeev Kumria as General Manager of H.E.L India
Experienced General Manager and commercial leader will scale H.E.L's operations in Indian growth markets, including biotechnology, process safety, and pharmaceutical industries. The appointment will enable H.E.L India to provide direct sales and marketing, service, and support operations to customers locally.
Avacta selects second pre|CISION™ pro-drug candidate for development
Cambridge and Wetherby, UK: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISION™ drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning…
Insightful Science acquires Omiq to add cloud-based machine learning to its flow cytometry capabilities
OMIQ is a powerful flow cytometry SaaS solution adopted by leading global biopharma labs.
The Native Antigen Company expands range of Norovirus-like particles
Oxford, UK: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced the expansion of its norovirus-like particle range, with the addition of six new reagents, including four which are unique to the market. These virus-like…
NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics
Shenzhen, China and Cambridge, UK: NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in China, and PhoreMost Limited (PhoreMost), the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, have announced an oncology drug discovery research collaboration.
H.E.L Group expands operations in India
H.E.L India opening further strengthens H.E.L's global presence with regional hub-based service and customer support. Expansion will focus on supporting high growth industries in India, including biotechnology, process safety, and pharmaceutical industries
Avacta provides update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, provides an update on the performance of the AffiDX® SARS-CoV-2 antigen lateral flow test (LFT) with the Omicron variant.
Samsara Therapeutics establishes Scientific Advisory Board
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics.
Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test receives CE mark for consumer self-testing
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.
Insightful Science acquires Protein Metrics to expand its R&D solution to include proteomics
San Diego, CA, 21 December 2021: Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire Protein Metrics Inc., a leading provider of biopharmaceutical protein characterization and proteomics analysis software. The acquisition expands the Company’s R&D value chain to widen the biopharmaceutical…
Bio-Rad introduces Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays
HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Bio-Plex™ Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only (RUO). The assays allow scientists to measure neutralizing antibodies quickly and efficiently against wild-type and significant…
Avacta announces AffiDx SARS-CoV-2 antigen lateral flow test detects the Omicron variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that the AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.
FUJIFILM Irvine Scientific opens European manufacturing facility
SANTA ANA, California, December 8, 2021: FUJIFILM Irvine Scientific, Inc., today announced that its new manufacturing facility in Tilburg, the Netherlands is now open and fully operational. The facility provides state-of-the-art Life Science manufacturing and joins locations in the U.S. and Japan to enable increased production capacity of cell culture media products; acting as a hub for…
Sixfold Bioscience completes $10.5M USD (£7.8M GBP) seed financing
London, UK, 02 Dec 2021: Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery systems, today announced it has raised a total of $10.5 million USD (£7.8 million GBP) in its seed funding round. The funding will support the continued development of the Company’s Mergo® RNA therapeutics delivery platform.
Avacta announces FDA approval of its Investigational New Drug (IND) application for AVA6000
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical…
Rebeca Sanchez Sarmiento joins Insightful Science and Dotmatics as Chief Financial Officer
Appointment brings extensive financial industry experience to drive global growth and build corporate value of newly combined organization that is aiming to make the world a healthier, cleaner and better place to live.
Bio-Rad introduces StarBright UltraViolet 400 Dye for flow cytometry
StarBright UltraViolet 400 Dye offers maximal brightness and narrow excitation and emission profiles for precise resolution.